New Release: Alpha testing version has been released.

Cefoxitin

J01D - Other beta-lactam antibacterials ATC J01DC01 Small molecule approved 1978 Parenteral Natural product Black-box warning

JFDA label: Foxitin IV/IM

⚠ Black-Box Warning

Mechanism of Action

Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.

Indications

Approved

  • Bone and joint infections
  • Gynecological infections
  • Intra-abdominal infections
  • Lower respiratory tract infections
  • Perioperative prophylaxis
  • Septicemia
  • Skin and skin structure infections
  • Urinary tract infections

Off-label

  • Bite wounds (animal)

Antimicrobial Spectrum

Expected / intrinsic spectrum (EUCAST breakpoints & labels) — not local resistance. Source: openfda-label.

Bacteria

OrganismActivityMIC
Bacteroides fragilis Active
Chlamydia trachomatis Active
Clostridium perfringen Active
Enterococcus faecalis Active
Escherichia coli Active
Haemophilus influenzae Active
Morganella morganii Active
Neisseria gonorrhoeae Active
Prevotella bivia Active
Proteus mirabilis Active
Proteus vulgaris Active
Staphylococcus aureus Active
Staphylococcus epidermidis Active
Streptococcus agalactiae Active
Streptococcus faecalis Active
Streptococcus pneumoniae Active
Streptococcus pyogenes Active

Class profile

gramStatusBoth
spectrumBreadthModerate
atypicalCoverageNo
isBactericidal1
moaCategoryCell wall synthesis inhibitor (beta-lactam, 2nd generation cephamycin)
pdIndexTime-dependent
postAntibioticEffectNone
mrsaCoverage0
resistanceMechanismsAmpC beta-lactamase,PBP mutations

Contraindications

Source: Lexicomp

  • Hypersensitivity to cefoxitin, any component of the formulation, or other cephalosporins Absolute

Adverse Reactions

Very Common >10%Common 1–10%Uncommon 0.1–1% Rare 0.01–0.1%Very Rare <0.01%Not Known

Other (1)

Common Gastrointestinal: Diarrhea

Dosing

Source: Lexicomp

Susceptible infections: IV: 1 to 2 g every 6 to 8 hours (IM injection is painful); up to 12 g daily Bite wounds (animal) (off-label use): IV: 1 g every 6 to 8 hours (IDSA [Stevens 2014]) Gas gangrene: IV: 2 g every 4 hours or 3 g every 6 hours (maximum daily dosage: 12 g daily) Intra-abdominal infection, complicated, community acquired, mild-to-moderate (Solomkin 2010): IV: 2 g every 6 hours for 4 to 7 days (provided source controlled) Moderately severe or severe infections: IV: 1 g every 4 hours or 2 g every 6 to 8 hours (maximum daily dosage: 8 g daily) Mycobacterium abscessus, not MTB or MAI (off-label use; Griffith 2007): IV: 12 g daily in divided doses with concomitant amikacin for ≥14 days Pelvic inflammatory disease (CDC [Workowski 2015]): Inpatients: IV: 2 g every 6 hours plus doxycycline for at least 24 to 48 hours after clinical improvement, followed by oral doxycycline to complete 14 days Outpatients: IM: 2 g as a single dose plus oral probenecid, followed by oral doxycycline (with or without concomitant metronidazole) for 14 days Surgical (perioperative) prophylaxis: Manufacturer's labeling (procedures other than Cesarian section): IV: 2 g 30 to 60 minutes prior to surgical incision, followed by 2 g every 6 hours for no more than 24 hours after surgery depending on the procedure Cesarean section: IV: 2 g as soon as umbilical cord is clamped as a single dose or 2 g as soon as umbilical cord is clamped followed by 2 g at 4 and 8 hours after the initial dose. Alternative recommendations: 2 g within 60 minutes prior to surgical incision. Doses may be repeated in 2 hours if procedure is lengthy or if there is excessive blood loss (Bratzler 2013). Uncomplicated cutaneous, urinary tract, lung infections: IV: 1 g every 6–8 hours (maximum daily dosage: 4 g daily)
(For additional information see "Cefoxitin: Pediatric drug information") Note: For group A beta-hemolytic streptococcal infections, antimicrobial therapy should be given for at least 10 days to guard against the risk of rheumatic fever or glomerulonephritis Infants >3 months, Children, and Adolescents: Manufacturer's labeling: IV: 80 to 160 mg/kg/day divided every 4 to 6 hours (maximum daily dose: 12 g daily) Alternative recommendations (Red Book [AAP] 2012): Mild-to-moderate infection: IV: Infants >3 months and Children: 80 mg/kg/day in divided doses every 6 to 8 hours (maximum daily dose: 4000 mg daily) Severe infection: IV: Infants >3 months and Children: 160 mg/kg/day in divided doses every 4 to 6 hours (maximum daily dose: 12 g daily) Infants >3 months and Children: Surgical (perioperative) prophylaxis: Manufacturer's labeling: IV: 30 to 40 mg/kg 30 to 60 minutes prior to surgical incision followed by 30 to 40 mg/kg/dose every 6 hours for no more than 24 hours after surgery depending on the procedure Alternative recommendations: Children ≥1 year: IV: 40 mg/kg within 60 minutes prior to surgical incision (maximum: 2000 mg per dose). Doses may be repeated in 2 hours if procedure is lengthy or if there is excessive blood loss (Bratzler 2013). Adolescents: Surgical (perioperative) prophylaxis: Refer to adult dosing.
Refer to adult dosing.
Loading dose: 1 to 2 g, followed by maintenance dosing according to CrCl. Maintenance dosage: CrCl 30 to 50 mL/minute: 1 to 2 g every 8 to 12 hours CrCl 10 to 29 mL/minute: 1 to 2 g every 12 to 24 hours CrCl 5 to 9 mL/minute: 0.5 to 1 g every 12 to 24 hours CrCl Hemodialysis: Loading dose: 1 to 2 g after each hemodialysis; maintenance dose as noted above based on creatinine clearance
There are no dosage adjustments provided in manufacturer’s labeling.

Warnings & Precautions

Source: Lexicomp

Hypersensitivity

Use with caution in patients with a history of penicillin allergy, especially IgE-mediated hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria). If a hypersensitivity reaction occurs, discontinue immediately.

Superinfection

Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment. Disease-related concerns:

GI disease

Use with caution in patients with a history of gastrointestinal disease, particularly colitis.

Renal impairment

Use with caution in patients with renal impairment; modify dosage in severe impairment.

Seizure disorders

Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures. Special populations:

Children

In pediatric patients ≥3 months of age, higher doses have been associated with an increased incidence of eosinophilia and elevated AST.

Elderly

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Elderly patients are more likely to have decreased renal function; use care in dose selection and monitor renal function. Other warnings/precautions:

Discontinuation of therapy

For group A beta-hemolytic streptococcal infections, antimicrobial therapy should be given for at least 10 days to guard against the risk of rheumatic fever or glomerulonephritis.

Pregnancy & Lactation

Pregnancy

Adverse events have not been observed in animal reproduction studies. Cefoxitin crosses the placenta and reaches the cord serum and amniotic fluid. Peak serum concentrations of cefoxitin during pregnancy may be similar to or decreased compared to nonpregnant values. Maternal half-life may be shorter at term. Pregnancy-induced hypertension increases trough concentrations in the immediate postpartum period. Cefoxitin is one of the antibiotics recommended for prophylactic use prior to cesarean delivery.

Lactation

Very small amounts of cefoxitin are excreted in breast milk. The manufacturer recommends that caution be exercised when administering cefoxitin to nursing women. Nondose-related effects could include modification of bowel flora. Cefoxitin pharmacokinetics may be altered immediately postpartum.

Monitoring

EfficacyCulture and susceptibility testing; clinical resolution (temperature, WBC, CRP, procalcitonin)
ToxicityRenal function (dose adjustment in renal impairment); hepatic function for hepatically cleared agents; signs of C. difficile infection (diarrhoea)
Clinical pearlCulture results guide de-escalation to narrower-spectrum therapy. Review antibiotic appropriateness at 48–72 h (antimicrobial stewardship).
CounselingComplete the full course. Report persistent diarrhoea, rash, or lack of improvement after 48–72 h.

Chemistry & Properties

2D structure
FormulaC16H17N3O7S2
Molecular weight427.46 g/mol
IUPAC name(6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CAS35607-66-0
PubChem CID441199
InChIKeyWZOZEZRFJCJXNZ-ZBFHGGJFSA-N
logP0.1 (XLogP 0.0)
Polar surface area148.26 Ų
H-bond acceptors / donors8 / 3
Drug-likeness (QED)0.41
Lipinski violations0
SMILESCO[C@@]1(NC(=O)Cc2cccs2)C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@@H]21

Biology & Pharmacokinetics

Pharmacokinetics predicted

Bioavailability70.0%
Half-life0.879 h
Volume of distribution0.196 L/kg
Protein binding44.7%
BBB penetrantNo

Transporters

BCRP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)MRP2 (Inhibitor)MRP3 (Inhibitor)MRP4 (Inhibitor)OAT3 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)PEPT1 (Inhibitor)P-gp (Substrate)PEPT1 (Substrate)

Drug–drug interactions (14, DDInter)

Interacting drugSeverityManagement
Amikacin moderate
Amikacin (liposome) moderate
Chloramphenicol moderate
Dicoumarol moderate
Ethinylestradiol moderate
Gentamicin moderate
Kanamycin moderate
Mycophenolic acid moderate
Neomycin moderate
Pemetrexed moderate
Picosulfuric acid moderate
Streptomycin moderate
Warfarin moderate
Heparin minor

Registered Products (1)

BrandForm / strengthPackAgentCitizen (JOD)
Foxitin IV/IM Vial 1 g 1 vial Sukhtian Group 5.730